04.04.2012 - After signing a broad licensing deal with Amgen Inc. that involves five experimental compounds, AstraZeneca is looking for partnerships with industry peers.
London/Stockholm – Martin Mackay, head of research at the London-headquartered drugmaker, which conducts its R&D in Sweden, said he was also considering smaller acquisitions, product licensing deals and more partnerships with big biotech and big pharma. The deal with Amgen buys rights to jointly develop and sell five of the US biotech major's experimental autoimmune drugs, and follows a similar tie-up in diabetes five years ago with Bristol-Myers Squibb. Amgen and AstraZeneca decided to jointly develop and commercialise five of Amgen's mAbs in the field of inflammation. The deal includes the anti-IL17R mAb brodalumab which will begin phase III testing this year in psoriasis. The monoclonal antibody is also being tested in phase II to treat psoriatic arthritis and asthma. The shared portfolio also includes: AMG 139, an undisclosed mAb in Phase Ib testing for Crohn's disease, AMG 157, a mAb in phase Ib testing for asthma and atopic dermatitis, AMG 181, an undisclosed mAb in Phase Ib testing for ulcerative colitis and Crohn's disease and finally AMG 557, a mAb in phase I for systemic lupus erythematosus (SLE). Amgen receives $50m upfront. The partners and will share costs and profits. The British-Swedish company will fund two thirds of costs until 2014, after which the partners will split costs equally. Amgen and AstraZeneca will share profits equally. AstraZeneca is in the lead for the development and commercialisation of AMG 139, AMG 157 and AMG 181, while its US partner is responsible for brodalumab and AMG 557. Analysts expect that AstraZeneca alone will invest about $250m in 2013 and 2014. However, the company declined to comment those numbers. The drugmaker is suffering from recent product failure and shrinking revenues. Mackay announced the intention to close other similar deals by the end of the year.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more